Download Peptinnovate

Harnessing the power of Nature:
First in Class, disease modifying medicines for asthma
Andrew Lightfoot, BSc, PhD, MBA
Chief Executive Officer
[email protected]
A new generation of anti-inflammatory medicines
Peptinnovate
263,000 patients followed over decades
show 75% reduced asthma with no side effects
Inverse relationship with
TB infection and asthma
High
incidence
Asthma Prevalence
Prevalence
(000,000)
000’000
40
75% reduction asthma
High quality publications
Shirakawa, 1997
30
20
No
TB
Linehan, 2007
No
TB
Obihara, 2006
Lighter-Fisher, 2012
10
TB
0
Normal
USA
TB
TB
Normal
TB
Europe
Normal
TB
Japan
263,000 individuals
 Asthma therapeutics is a growing $22bn market where major drugs
are failing or are coming off patent in 2016
 Pharma companies acquiring innovative new medicines at an early
stage - potential for early exit
2
Peptinnovate
40,000 years of co-evolution with
man provides a solution for asthma
 2002 – 2009 researchers in the UK uncover the causative agent for
switching off asthma
 Single molecules designed by TB to be safe and efficacious in man
TB protein secreted
into the human body
Prof. Clive Page
Asthma expert
Kings College London
Prof. Anthony Coates
Professor of microbiology
St Georges Hospital
3
Unique and remarkable
properties to modify
lung inflammation
Peptinnovate
Peptinnovate’s Innovation: Creating a
first in class medicine for asthma from TB
Drug Discovery
Protein designed by TB
New drug molecules
PIN201104
Preclinical development
Safety and regulatory studies
Manufacturing and safety and efficacy studies
Initial Clinical
testing
Differentiating studies in man
Patent granted in
all major territories
IP owned 100% by
Peptinnovate
Capital required: $4m (@$15m) $4m
Valuations:
Ph1 ready $80m Ph2 ready $330m
 Unique position, efficacy already proven in man (TB bacteria)
 Small investment required to early exit to pharma company
4
Peptinnovate
Asthma response uniquely modified;
Gold standard asthma drug does not work

Single dose of PIN201104 modifies the response to house dust mite allergy –
no other drug can do this

Fluticasone, the steroid in Advair ($9bn sales pa), does not work in this assay

Exquisite safety profile observed with Peptinnovate’s PIN201104 (TB heritage)

Industry focused on filling their pipelines with new medicines
Data prepared by GSK
exclusively for Peptinnovate
Fluticasone ($9bn sales pa)
does not work in this paradigm
5
Peptinnovate
Limited funding required,
Exceptional returns and short time to exit
Value
$000m
Discussions ongoing with
the key Pharma companies
$330m
$ valuations
$ capital required
$80m
$15m
$4m
$15m
Phase 1
Human
safety
$4m
2002
2009
Pre-seed $5m
2016
Phase 2
Human Efficacy
2018
Time
Position in July 2015
 Valuations based on change of phase with full rNPV calculations
 David Beadle, former Head of
European Pharmaceutical Equity
Research
 Evidence of early exits in this space: Ph1 $200m; Ph2 $500m
6
Peptinnovate
Peptinnovate has built a highly experienced &
proven Management Team, Board and Advisors
Dr Andrew Lightfoot CEO
20 years in pharma
Discovery
Dr Clare Burgess COO
23 years in pharma
Clinical
Professor Clive Page
Chairman
Dr Thierry Plouvier
Non-executive director
Dr Nicky Cooper CSO
30 years in pharma
Biology
Prof.Trevor Jones MBE
Advisor
Richard Nagle (Exec Dir)
30 years in life sciences
Commercial
Michael Albisser CFO
20 years in finance
industry
Mr Gunnar Walstam
Investor and senior advisor
Mr Christopher Smith
Investor and senior advisor
 Much lower risk profile due to proven asthma reduction with 75% in 5
statistically significant respiratory human studies with no known side effects
 Seed funding sought: $1.5m available out of a total of $4m (pre-money $15m)
to be phase 1 ready ($80m valuation)
 Potential for early exit in 24 months via licence / trade sale to pharma partner
7
Peptinnovate